Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948601 | 0.94 | CASP2 (0.48) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL23489532 | 0.92 | MEN1 (0.54) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL16123439 | 0.85 | MCL1 (0.47) | CASP2EPHX1MEN1KMT2A | |
| SCHEMBL22931570 | 0.83 | PAOX (0.53) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL9879638 | 0.82 | CES2 (0.55) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL16946573 | 0.82 | MEN1 (0.44) | CASP2MEN1KMT2AZDHHC20ZDHHC2 | |
| SCHEMBL15341568 | 0.81 | CES2 (0.58) | CASP2NAAAEPHX1FAAH | |
| SCHEMBL12360826 | 0.80 | CASP2 (0.62) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL12314650 | 0.80 | CASP2 (0.47) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL13990678 | 0.78 | CASP2 (0.55) | CASP2NAAAEPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000876-A1 | METHOD FOR THE VACCINATION AGAINST HIV | BIONOR IMMUNO AS (NO) | 2017-01-05 | — | — | US | disclosed |
| US-20170000876-A1 | METHOD FOR THE VACCINATION AGAINST HIV | BIONOR IMMUNO AS (NO) | 2017-01-05 | — | — | US | disclosed |
| WO-2015110659-A1 | METHODS OF IMMUNIZATION WITH A VACCINE INDUCING A HUMORAL IMMUNE RESPONSE AND WITH A VACCINE INDUCING A CELLULAR IMMUNE RESPONSE | BIONOR IMMUNO AS (NO) | 2015-07-30 | — | — | WO | disclosed |
| US-20150174235-A1 | VACCINE | BIONOR IMMUNO AS (NO) | 2015-06-25 | — | — | US | disclosed |
| US-20150174235-A1 | VACCINE | BIONOR IMMUNO AS (NO) | 2015-06-25 | — | — | US | disclosed |
| US-20150132255-A1 | HIV VACCINE | BIONOR IMMUNO AS (NO) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150132255-A1 | HIV VACCINE | CD4, CCR5, FURIN | CASP2 2906/4885NAAA 3273/4885EPHX1 3576/4885 |
| US-20170000876-A1 | METHOD FOR THE VACCINATION AGAINST HIV | CD4, KLK3, CCR5 | CASP2 2201/4885NAAA 916/4885EPHX1 2333/4885 |
| US-20150174235-A1 | VACCINE | HDAC5, HDAC9, HDAC4 | CASP2 1108/4885NAAA 795/4885EPHX1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.